argenex (ARGX) Projected to Post Earnings on Thursday

argenex (NASDAQ:ARGX) is expected to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect argenex to post earnings of $4.34 per share and revenue of $909.8630 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

argenex (NASDAQ:ARGX) last issued its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.90. The firm had revenue of $866.79 million during the quarter, compared to analysts’ expectations of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. On average, analysts expect argenex to post $3 EPS for the current fiscal year and $11 EPS for the next fiscal year.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $829.83 on Tuesday. The stock has a market capitalization of $51.09 billion, a price-to-earnings ratio of 42.56, a PEG ratio of 0.89 and a beta of 0.46. argenex has a 1-year low of $510.05 and a 1-year high of $855.46. The company has a 50 day moving average price of $756.03 and a 200 day moving average price of $647.67.

Institutional Trading of argenex

Several institutional investors have recently made changes to their positions in ARGX. Geneos Wealth Management Inc. boosted its position in shares of argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares in the last quarter. Rakuten Securities Inc. boosted its position in shares of argenex by 113.1% during the 2nd quarter. Rakuten Securities Inc. now owns 130 shares of the company’s stock valued at $72,000 after acquiring an additional 69 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of argenex by 60.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after acquiring an additional 50 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of argenex by 49.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 175 shares of the company’s stock valued at $96,000 after acquiring an additional 58 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of argenex by 120.1% during the 2nd quarter. Quantbot Technologies LP now owns 306 shares of the company’s stock valued at $169,000 after acquiring an additional 167 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ARGX shares. HC Wainwright increased their target price on shares of argenex from $720.00 to $774.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Truist Financial raised their target price on shares of argenex from $700.00 to $918.00 and gave the company a “buy” rating in a research note on Monday, September 15th. Wall Street Zen upgraded shares of argenex from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus set a $882.00 target price on shares of argenex in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $817.53.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.